

ABX-PF1 DIV2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia I. Ouspenski
Group : 1644
Applicants : Douglas Charles Hanson et al.
Application No.: : 10/776,649
Confirmation No. : 5045
Filed : February 10, 2004
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

RECEIVED
CENTRAL FAX CENTER

MAY 09 2006

New York, New York
March , 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER BY ASSIGNEE

Pfizer Inc is the joint owner of 100% interest in the above-captioned application, in U.S. Patent No. 6,682,736 B1, issued January 27, 2004, and in second application serial number 10/612,497, filed July 1, 2003. Pfizer Inc hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,682,736 B1, or any patent issuing on said second application, including any patent term extensions, restorations or adjustments for said patent available under all applicable statutes including 35 U.S.C. §154 through 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 6,682,736 B1, or any patent issuing on said second application. The owner hereby agrees that any patent so granted on the above-captioned application shall be enforceable only for and during such period that the legal title to it and to the above-identified granted patent and to said second application shall be commonly owned. This agreement runs with any patent granted on the above-captioned application, and is binding upon the grantee, its successors or assigns.

05/10/2006 HGUTEMA1 00000043 061075 10776649

01 FC:1814 130.00 DA

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the above-captioned application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 to 156 and 173 of the above-identified grant patent or any patent issuing on said second application as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 6,682,736 B1 or prior to the grant of any patent issuing on said second application, in the event that the granted patent expires for failure to pay a maintenance fee, is held unenforceable and/or invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 35 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or its term is in any manner shortened prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The undersigned states that he/she is authorized to sign the document on behalf of Pfizer Inc as assignee of the above-captioned application, that the evidentiary documents relating to the assignment of the above application have been reviewed, and he/she certifies that, to the best of assignee's knowledge and belief, title to the above application is in assignee by virtue of assignment(s) recorded in the U.S. Patent and Trademark Office on March 18, 2002, in U.S. Patent Application No. 09/472,087 (now issued as U.S. Patent No. 6,682,736 B1), at Reel 012709, Frame 0596.

This Terminal Disclaimer is accompanied by a fee transmittal form authorizing payment of the appropriate fee under 37 C.F.R. § 1.20(d).

Check either box 1 or 2 below, if appropriate.

1. For submission on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

2. The undersigned is an attorney of record.

Respectfully submitted,

PFIZER INC

Date: March 24, 2006

Peter C. Richardson

Peter C. Richardson
Title: Senior Vice-President,
Associate General Counsel – Intellectual Property
Pfizer Inc

Pfizer Inc Legal Department
150 East 42nd Street
MS 150/5/49
New York, New York 10017-5612
(212) 573-7805